5,817 Shares in AstraZeneca PLC $AZNCF Acquired by Saranac Partners Ltd

Saranac Partners Ltd purchased a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,817 shares of the company’s stock, valued at approximately $876,000.

Separately, Boston Common Asset Management LLC boosted its holdings in shares of AstraZeneca by 5.6% in the third quarter. Boston Common Asset Management LLC now owns 192,589 shares of the company’s stock valued at $28,992,000 after acquiring an additional 10,154 shares during the period. 40.87% of the stock is owned by institutional investors.

AstraZeneca Stock Performance

Shares of AZNCF opened at $187.10 on Thursday. The company’s 50 day simple moving average is $186.75 and its 200-day simple moving average is $176.61. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.